Recruiting

Testing a new medication to slow memory loss in Alzheimer's disease

Plain-English translation of NCT06850597 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is testing whether , a medication taken by mouth once daily, can help slow or reduce memory loss and improve thinking skills in people with mild cognitive impairment or early-stage Alzheimer's disease. Researchers will compare how well this medication works compared to a placebo (a pill with no active medicine) by measuring changes in memory, attention, and how well people can manage daily tasks. The study also aims to make sure the medication is safe to use in this patient population.

Alzheimer's disease and related memory problems cause progressive decline in thinking and daily functioning, and current treatments have limited effectiveness. This trial is exploring whether this medication might help protect the brain and slow cognitive decline in people in the early stages of disease.

Do you qualify?

You likely qualify if…

you are between 55 and 90 years old
you have been diagnosed with mild cognitive impairment related to Alzheimer's disease or mild to moderate Alzheimer's dementia
you have a score of 17–30 on the Mini-Mental State Exam (a standard memory and thinking test)
you have a close family member or caregiver who can help support you during the study
you have completed at least 6 years of formal education
if you are taking other Alzheimer's medications, they must have been at a stable dose for at least 60–120 days before you enter the study

You likely don't qualify if…

you are pregnant, breastfeeding, or a woman of childbearing age not using effective contraception
you have serious liver disease or kidney disease (including very low kidney function)
you have abnormal blood counts (very low white blood cells, immune cells, or lymphocytes)
you have or have had other neurological conditions such as Parkinson's disease, multiple sclerosis, or previous stroke
you are currently taking benzodiazepines (anti-anxiety medications) or have a current psychiatric condition such as bipolar disorder or psychosis that your doctor believes would interfere with the study

What participation looks like

If you join this study, you will be randomly assigned to take either the study medication (480 mg daily) or a placebo pill that looks identical. You and the researchers will not know which you're taking—that's why it's called 'double-blind.' You will attend visits where researchers will test your memory and thinking with standard exams, check how well you're managing daily activities, assess your mood and quality of life, and monitor your safety with blood tests and brain imaging. A family member or caregiver will be asked to attend some visits and help track how you're doing at home.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

Poland

Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz, Lodz, Łódź Voivodeship